UK markets open in 5 hours 13 minutes
  • NIKKEI 225

    29,926.28
    -573.77 (-1.88%)
     
  • HANG SENG

    23,818.71
    -280.43 (-1.16%)
     
  • CRUDE OIL

    70.74
    +0.45 (+0.64%)
     
  • GOLD FUTURES

    1,764.70
    +0.90 (+0.05%)
     
  • DOW

    33,970.47
    -614.41 (-1.78%)
     
  • BTC-GBP

    31,211.66
    -3,471.34 (-10.01%)
     
  • CMC Crypto 200

    1,065.74
    -68.64 (-6.05%)
     
  • ^IXIC

    14,713.90
    -330.06 (-2.19%)
     
  • ^FTAS

    3,986.90
    -36.43 (-0.91%)
     

Global Gastroesophageal Reflux Disease Therapeutics Market (2021 to 2026) - by Drug Type, Distribution Channel and Region

·8-min read

Dublin, Sept. 10, 2021 (GLOBE NEWSWIRE) -- The "Global Gastroesophageal Reflux Disease (GERD) Therapeutics Market - Analysis By Drug Type, Distribution Channel, By Region, and By Country (2021 Edition): Market Insights and Forecast with Impact of COVID-19 (2021-2026)" report has been added to ResearchAndMarkets.com's offering.

Global Gastroesophageal Reflux Disease (GERD) Therapeutics Market was valued at USD 5.5 billion in the year 2020. The key factors driving growth in the global Gastroesophageal Reflux Disease Therapeutics market is increased public awareness of the disease and its symptoms. The growing incidence of heartburn is likely to create new economic prospects for acid-reducing medications and proton pump inhibitors, resulting in the rapid growth of GERD therapeutics market. Other potential includes an increase in risk of GERD disease in emerging nations and technological advancements that allow for speedier diagnosis of the condition.

Protein pump inhibitors (PPIs) are the front line therapy for the treatment of GERD. The market of GERD is very large in the US and in European countries and mostly catered by PPIs. Although PPIs control the major share of the market but with PPIs providing limited relief and the treatment generally relapsing within 6-months, the market for acid blockers like Vonoprazan looks very lucrative with physicians also supports its efficacy in GERD management. Also, the US GERD market is highly price sensitive because of the availability of generics in the market and hence any drug, even with higher efficiency, will have to price rationally to gain share of the market.

The increasing prevalence of gastroesophageal reflux disease is correlated with the increasing prevalence of obesity in many countries and presence of other poor diet and lifestyle factors. Several environmental factors and the prominent lifestyle evolution to sedentary habits such as a high dietary fat intake, shorter dinner-to-bed time, and frequent smoking and alcohol consumption have been proven as the high risk factors associated with the prevalence of gastroesophageal reflux diseases.

North America region dominates the Gastroesophageal Reflux Disease Therapeutics Market. High incidence of obesity-driven GERD and innovation in drugs in GERD treatments are factors that have helped cement the potential of the North America GERD therapeutics market. Moreover, high per capita expenditure on healthcare coupled with extended life expectancy of consumers in the region has been creating a sustainable demand for the superior treatment for the GERD in North America.

Scope of the Report

  • The report presents the analysis of Gastroesophageal Reflux Disease Therapeutics Market for the historical period of 2016-2020 and the forecast period of 2021-2026.

  • The report analyses the Gastroesophageal Reflux Disease Therapeutics Market by Drug Type (Antacids, H2 Receptor Blockers and Proton Pump Inhibitors) and Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies).

  • The major regional markets (North America, Europe, Asia Pacific) have been analysed, along with country coverage of North America, Europe and Asia Pacific) and By Country (United States, Canada, Germany, France, United Kingdom, Spain, Italy, China, Japan and India.

  • The market dynamics such as growth drivers, market trends and challenges are analysed in-depth.

  • The competitive landscape of the market, along with the company profiles of leading players (Phathom Pharmaceuticals, Eisai, Takeda Pharmaceutical Company, Daewoong Pharmaceutical, Ironwood Pharmaceuticals, Johnson & Johnson, EndoGastric Solutions, CHEPLAPHARM Arzneimittel, Merck & Co. and Olympus Corporation.) are also presented in detail.

Key Topics Covered:

1. Research Methodology and Executive Summary

1. Report scope & Methodology

2. Strategic Recommendations

3. Global Gastroesophageal Reflux Disease Therapeutics Market Product Overview

4. Global Gastroesophageal Reflux Disease Therapeutics Market: An Analysis
4.1 Market Size, By Value, Year 2016-2026
4.2 COVID-19 Impact on Gastroesophageal Reflux Disease Therapeutics Market

5. Global Gastroesophageal Reflux Disease Therapeutics Market Segmentation By Drug Type (By Value)
5.1 Competitive Scenario of Global Gastroesophageal Reflux Disease Therapeutics Market: By Drug Type
5.2 Antacids- Market Size and Forecast (2016-2026)
5.3 H2 Receptor Blockers- Market Size and Forecast (2016-2026)
5.4 Proton Pump Inhibitors- Market Size and Forecast (2016-2026)

6. Global Gastroesophageal Reflux Disease Therapeutics Market Segmentation By Distribution Channel (By Value)
6.1 Competitive Scenario of Global Gastroesophageal Reflux Disease Therapeutics Market: By Distribution Channel
6.2 Hospital Pharmacies- Market Size and Forecast (2016-2026)
6.3 Retail Pharmacies- Market Size and Forecast (2016-2026)
6.4 Online Pharmacies- Market Size and Forecast (2016-2026)

7. Global Gastroesophageal Reflux Disease Therapeutics Market: Regional Analysis
7.1 Competitive Scenario of Global Gastroesophageal Reflux Disease Therapeutics Market: By Region

8. North America Gastroesophageal Reflux Disease Therapeutics Market: An Analysis (2016-2026)
8.1 North America Gastroesophageal Reflux Disease Therapeutics Market: Size and Forecast (2016-2026), By Value
8.2 North America Gastroesophageal Reflux Disease Therapeutics Market - Prominent Companies
8.3 Market Segmentation By Drug Type (Antacids, H2 Receptor Blockers and Proton Pump Inhibitors)
8.4 Market Segmentation By Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies)
8.5 North America Gastroesophageal Reflux Disease Therapeutics Market: Country Analysis
8.6 Market Opportunity Chart of North America Gastroesophageal Reflux Disease Therapeutics Market - By Country, By Value (Year-2026)
8.7 Competitive Scenario of North America- By Country
8.8 United States Gastroesophageal Reflux Disease Therapeutics Market: Size and Forecast (2016-2026), By Value
8.9 Prominent Companies in Gastroesophageal Reflux Disease Therapeutics Market
8.10 United States Gastroesophageal Reflux Disease Therapeutics Market Segmentation By Drug Type and Distribution Channel.
8.11 Canada Gastroesophageal Reflux Disease Therapeutics Market: Size and Forecast (2016-2026), By Value
8.12 Canada Gastroesophageal Reflux Disease Therapeutics Market Segmentation By Drug Type and Distribution Channel.

9. Europe Gastroesophageal Reflux Disease Therapeutics Market: An Analysis (2016-2026)
9.1 Europe Gastroesophageal Reflux Disease Therapeutics Market: Size and Forecast (2016-2026), By Value
9.2 Europe Gastroesophageal Reflux Disease Therapeutics Market - Prominent Companies
9.3 Market Segmentation By Drug Type (Antacids, H2 Receptor Blockers and Proton Pump Inhibitors)
9.4 Market Segmentation By Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies)
9.5 Europe Gastroesophageal Reflux Disease Therapeutics Market: Country Analysis
9.6 Market Opportunity Chart of Europe Gastroesophageal Reflux Disease Therapeutics Market - By Country, By Value (Year-2026)
9.7 Competitive Scenario of Europe- By Country
9.8 Germany Gastroesophageal Reflux Disease Therapeutics Market: Size and Forecast (2016-2026), By Value
9.9 Prominent Companies in Gastroesophageal Reflux Disease Therapeutics Market
9.10 Germany Gastroesophageal Reflux Disease Therapeutics Market Segmentation By Drug Type and Distribution Channel.
9.11 France Gastroesophageal Reflux Disease Therapeutics Market: Size and Forecast (2016-2026), By Value
9.12 France Gastroesophageal Reflux Disease Therapeutics Market Segmentation By Drug Type and Distribution Channel.
9.13 United Kingdom Gastroesophageal Reflux Disease Therapeutics Market: Size and Forecast (2016-2026), By Value
9.14 Prominent Companies in Gastroesophageal Reflux Disease Therapeutics Market
9.15 United Kingdom Gastroesophageal Reflux Disease Therapeutics Market Segmentation By Drug Type and Distribution Channel.
9.16 Italy Gastroesophageal Reflux Disease Therapeutics Market: Size and Forecast (2016-2026), By Value
9.17 Italy Gastroesophageal Reflux Disease Therapeutics Market Segmentation By Drug Type and Distribution Channel.
9.18 Spain Gastroesophageal Reflux Disease Therapeutics Market: Size and Forecast (2016-2026), By Value
9.19 Spain Gastroesophageal Reflux Disease Therapeutics Market Segmentation By Drug Type and Distribution Channel.

10. Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market: An Analysis (2016-2026)
10.1 Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market: Size and Forecast (2016-2026), By Value
10.2 Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market - Prominent Companies
10.3 Market Segmentation By Drug Type (Antacids, H2 Receptor Blockers and Proton Pump Inhibitors)
10.4 Market Segmentation By Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies)
10.5 Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market: Country Analysis
10.6 Market Opportunity Chart of Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market - By Country, By Value (Year-2026)
10.7 Competitive Scenario of Asia Pacific- By Country
10.8 China Gastroesophageal Reflux Disease Therapeutics Market: Size and Forecast (2016-2026), By Value
10.9 China Gastroesophageal Reflux Disease Therapeutics Market Segmentation By Drug Type and Distribution Channel.
10.10 Japan Gastroesophageal Reflux Disease Therapeutics Market: Size and Forecast (2016-2026), By Value
10.11 Prominent Companies in Gastroesophageal Reflux Disease Therapeutics Market
10.12 Japan Gastroesophageal Reflux Disease Therapeutics Market Segmentation By Drug Type and Distribution Channel.
10.13 India Gastroesophageal Reflux Disease Therapeutics Market: Size and Forecast (2016-2026), By Value
10.14 India Gastroesophageal Reflux Disease Therapeutics Market Segmentation By Drug Type and Distribution Channel.

11. Global Gastroesophageal Reflux Disease Therapeutics Market Dynamics
11.1 Global Gastroesophageal Reflux Disease Therapeutics Market Drivers
11.2 Global Gastroesophageal Reflux Disease Therapeutics Market Restraints
11.3 Global Gastroesophageal Reflux Disease Therapeutics Market Trends

12. Market Attractiveness
12.1 Market Attractiveness Chart of Global Gastroesophageal Reflux Disease Therapeutics Market - By Drug Type, By Value (Year-2026)
12.2 Market Attractiveness Chart of Global Gastroesophageal Reflux Disease Therapeutics Market - By Distribution Channel, By Value (Year-2026)
12.3 Market Attractiveness Chart of Global Gastroesophageal Reflux Disease Therapeutics Market - By Region, By Value (Year-2026)

13. Competitive Landscape
13.1 Market Share Analysis
13.2 Gastroesophageal Reflux Disease Therapeutics Pipeline

14. Company Profiles (Business Description, Financial Analysis, Business Strategy)
14.1 Phathom Pharmaceuticals
14.2 Eisai
14.3 Takeda Pharmaceutical Company
14.4 Daewoong Pharmaceutical
14.5 Ironwood Pharmaceuticals
14.6 Johnson & Johnson
14.7 EndoGastric Solutions
14.8 CHEPLAPHARM Arzneimittel
14.9 Merck & Co.
14.10 Olympus Corporation

For more information about this report visit https://www.researchandmarkets.com/r/ta6ypw

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting